Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NT5E | P21589 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2520516 | 0.88 | AHCY (0.47) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL22855175 | 0.88 | AHCY (0.47) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL25867818 | 0.82 | PNP (0.39) | LMNAADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL22939403 | 0.81 | NT5E (0.37) | NT5ECHKAADORA3ADORA2AADORA2B | |
| SCHEMBL22939597 | 0.80 | ADORA3 (0.35) | NT5ECHKAADORA3ADORA2AADORA2B | |
| SCHEMBL25659855 | 0.80 | AHCY (0.45) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL26295158 | 0.79 | AHCY (0.37) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL2524440 | 0.78 | PDE4D (0.53) | LMNANT5EADORA3ADORA2AADORA1 | |
| SCHEMBL2520562 | 0.78 | AHCY (0.47) | AHCYLMNANT5EHIF1ACHKA | |
| SCHEMBL12214180 | 0.74 | AHCY (0.41) | AHCYLMNANT5EHIF1ACHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2020031131-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | AHCY 248/4885LMNA 3687/4885NT5E 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.